ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel

Chinese Journal of Cancer

Volumn 34, Issue 3, 2015, Pages 1-6

  Kathawala, Rishil J ^a   Wang, Yi Jun ^a   Shukla, Suneet ^b   Zhang, Yun Kai ^a   Alqahtani, Saeed ^c   Kaddoumi, Amal ^c   Ambudkar, Suresh V ^b   Ashby, Charles R ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

ATP binding cassette (ABC) transporters; ATP binding cassette subfamily B member 1 (ABCB1); ATP binding cassette subfamily C member 10 (ABCC10); Cabazitaxel; Paclitaxel; Taxane

Indexed keywords

ADENOSINE TRIPHOSPHATE; CABAZITAXEL; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCC10 PROTEIN, HUMAN; BRIDGED COMPOUND; MULTIDRUG RESISTANCE PROTEIN; TAXANE; TAXOID;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN EXPRESSION; SPECTROPHOTOMETRY; DRUG RESISTANCE; HEK293 CELL LINE; MULTIDRUG RESISTANCE; TUMOR CELL LINE;

ATP-BINDING CASSETTE TRANSPORTERS; BRIDGED-RING COMPOUNDS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PACLITAXEL; TAXOIDS;

EID: 84924527935     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.1186/s40880-015-0003-0     Document Type: Article

References (26)

1. Kathawala RJ, Sodani K, Chen K, Patel A, Abuznait AH, Anreddy N, et al. Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study. Mol Cancer Ther. 2014;13:714–23.
2. Yin S, Bhattacharya R, Cabral F. Human mutations that confer paclitaxel resistance. Mol Cancer Ther. 2010;9:327–35.
3. Kathawala RJ, Wang YJ, Ashby Jr CR, Chen ZS. Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chin J Cancer. 2014;33:223–30.
4. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.
5. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999;17:1061–70.
6. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152–62.
7. Ueda K, Cornwell MM, Gottesman MM, Pastan I, Roninson IB, Ling V, et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun. 1986;141:956–62.
8. Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr. 2001;33:481–91.
9. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 2007;453:675–84.
10. Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett. 2001;162:181–91.
11. Sodani K, Patel A, Kathawala RJ, Chen ZS. Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer. 2012;31:58–72.
12. Vrignaud P, Semiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res. 2013;19:2973–83.
13. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat Rev Drug Discov. 2010;9:677–8.
14. Kathawala RJ, Gupta P, Ashby Jr CR, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2014;Dec 10. doi:10.1016/j.drup.2014.11.002. [Epub ahead of print].
15. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009;69:178–84.
16. Wang YJ, Kathawala RJ, Zhang YK, Patel A, Kumar P, Shukla S, et al. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem Pharmacol. 2014;90:367–78.
17. Kathawala RJ, Wei L, Anreddy N, Chen K, Patel A, Alqahtani S, et al. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget. 2014. [Epub ahead of print].
18. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet. 1985;11:117–26.
19. Fung KL, Pan J, Ohnuma S, Lund PE, Pixley JN, Kimchi-Sarfaty C, et al. MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res. 2014;74:598–608.
20. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003;63:351–8.
21. Kathawala RJ, Chen JJ, Zhang YK, Wang YJ, Patel A, Wang DS, et al. Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Int J Oncol. 2014;44:1634–42.
22. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM, et al. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry. 1998;37:5010–9.
23. Ambudkar SV. Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol. 1998;292:504–14.
24. Yang D, Kathawala RJ, Chufan EE, Patel A, Ambudkar SV, Chen ZS, et al. Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). Future Oncol. 2014;10:1827–41.
25. Nightingale G, Ryu J. Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P T. 2012;37:440–8.
26. Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, et al. Mechanisms of resistance to cabazitaxel. Mol Cancer Ther. 2015;14:193–201.